Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

Impact · against what's priced in

The article provides no new catalysts for Corcept Therapeutics, as the current stock price already reflects Lifyorli's FDA approval, its initial sales figures, and Korlym's recent growth. For Roche, the mention of a clinical partnership is marginally positive but lacks materiality for a company of its scale.

CORT+0.00: Already priced in
The price assumes: The FDA approval of Lifyorli for ovarian cancer and its initial $47.6 million quarterly contribution are fully paid for

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

What matters in this story

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

What matters in this story

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

How each ticker is affected

Connected tickers

Track these names every morning.

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

Is Eli Lilly Stock a Buy Right Now?

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

What matters in this story

Next reads from the same story arc

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

What matters in this story

Next reads from the same story arc

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

How each ticker is affected

Connected tickers

Track these names every morning.

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

Is Eli Lilly Stock a Buy Right Now?

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series